340 related articles for article (PubMed ID: 30068939)
1. Hippo signaling dysfunction induces cancer cell addiction to YAP.
Han H; Yang B; Nakaoka HJ; Yang J; Zhao Y; Le Nguyen K; Bishara AT; Mandalia TK; Wang W
Oncogene; 2018 Dec; 37(50):6414-6424. PubMed ID: 30068939
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation.
Peng C; Zhu Y; Zhang W; Liao Q; Chen Y; Zhao X; Guo Q; Shen P; Zhen B; Qian X; Yang D; Zhang JS; Xiao D; Qin W; Pei H
Mol Cell; 2017 Nov; 68(3):591-604.e5. PubMed ID: 29100056
[TBL] [Abstract][Full Text] [Related]
3. Hippo-YAP signaling pathway: A new paradigm for cancer therapy.
Ma Y; Yang Y; Wang F; Wei Q; Qin H
Int J Cancer; 2015 Nov; 137(10):2275-86. PubMed ID: 25042563
[TBL] [Abstract][Full Text] [Related]
4. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
5. Targeting YAP and Hippo signaling pathway in liver cancer.
Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
[TBL] [Abstract][Full Text] [Related]
6. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
[TBL] [Abstract][Full Text] [Related]
7. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
9. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
11. Regulation of YAP by mechanical strain through Jnk and Hippo signaling.
Codelia VA; Sun G; Irvine KD
Curr Biol; 2014 Sep; 24(17):2012-7. PubMed ID: 25127217
[TBL] [Abstract][Full Text] [Related]
12. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
[TBL] [Abstract][Full Text] [Related]
13. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung.
Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA
J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985
[TBL] [Abstract][Full Text] [Related]
14. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
15. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.
Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J
Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929
[TBL] [Abstract][Full Text] [Related]
16. Hippo-yap signaling in ocular development and disease.
Lee M; Goraya N; Kim S; Cho SH
Dev Dyn; 2018 Jun; 247(6):794-806. PubMed ID: 29532607
[TBL] [Abstract][Full Text] [Related]
17. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
18. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
19. The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes.
Wennmann DO; Vollenbröker B; Eckart AK; Bonse J; Erdmann F; Wolters DA; Schenk LK; Schulze U; Kremerskothen J; Weide T; Pavenstädt H
Cell Death Dis; 2014 Nov; 5(11):e1519. PubMed ID: 25393475
[TBL] [Abstract][Full Text] [Related]
20. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
